Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001220-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of this study is to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve sustained virological response (SVR) when treated with PEG-Intron plus REBETOL.


Critère d'inclusion

  • Chronic Hepatitis C genotype 1